Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression?Ottobelli L. · Manni G.L. · Centofanti M. · Iester M. · Allevena F. · Rossetti L.
aEye Clinic, San Paolo Hospital, University of Milan, Milan, bDipartimento di Scienze Cliniche e Medicina Traslazionale, University of Rome Tor Vegata, and cFondazione G.B. Bietti per l'Oftalmologia, IRCCS, Rome, and dLaboratorio Clinico Anatomo-Funzionale per la Diagnosi e il Trattamento del Glaucoma e delle Malattie Neurooftalmologiche, Clinica Oculistica, DINOGMI, University of Genoa, Genoa, Italy
Purpose: To assess the effect of citicoline on visual field rates of progression in patients with progressing glaucoma. Patients and Methods: Forty-one patients with a diagnosis of progressing glaucoma received citicoline in oral solution for 2 years. Included were patients with a disease progression of at least -1 dB/year (at MD, mean deviation) for at least 3 years before entering the study despite controlled intraocular pressure (IOP). Patients were followed with 4 visual field examinations per year for 2 years. Results: At baseline, the mean rate of progression was -1.1 (±0.7) dB/year despite the fact that the IOP had been below 18 mm Hg for at least 3 years. At study inclusion, the mean IOP was 15.5 (±2.6) mm Hg and the mean MD was -9.2 (±6.7) dB in the worst eye. Starting from the first cycle of treatment with citicoline, the mean rate of progression significantly changed to -0.15 (±0.3) dB/year at the end of the study (p = 0.01). Conclusions: This study seems to indicate that supplementation with citicoline might significantly slow down glaucomatous rates of progression.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50